The present invention relates to an adenosine A
3
receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II″), (III″), (IV″), (V″), (VI″), (VII″), (VIII″) and (XIII″) and their preparation.
本发明涉及一种通式(I)的
腺苷A3受体
配体,其中最好是
拮抗剂,包括其盐、溶剂合物或异构体(互变异构体、去构异构体和光学活性异构体),以及含有该
配体的制药组合物,该
配体的使用,其制备以及通式(II")、(III")、(IV")、(V")、(VI")、(VII")、(VIII")和(XIII")的
配体的
中间体以及它们的制备。